AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012
May 29, 2012
29864_dirs_2012-05-29_c562259b-077e-460e-9544-f3b629372400.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-24
Reporting Person: Kelly Lisa (SVP, Human Resources)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-05-24 | Common Stock | S | 900 | $62.74 | Disposed | 22355 | Direct |
| 2012-05-24 | Common Stock | S | 5106 | $63.38 | Disposed | 17249 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1667 | Indirect |
Footnotes
F1: Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $62.74 (range $62.25 to $62.99).
F3: Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $63.38 (range $63.06 to $63.62).